<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055912</url>
  </required_header>
  <id_info>
    <org_study_id>CK-LX2401</org_study_id>
    <nct_id>NCT01055912</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure</brief_title>
  <official_title>Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Efficacy and Safety Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioKine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiokine Biopharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioKine Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of oral lixivaptan capsules in patients&#xD;
      with congestive heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diuretics are used extensively in the treatment of patients with CHF, and their efficacy is&#xD;
      well established. However, there is a tendency for currently used diuretics to increase&#xD;
      afterload and deplete electrolytes, and in many patients ventricular function continues to&#xD;
      deteriorate over time.&#xD;
&#xD;
      Loop diuretics, such as furosemide, also have known negative effects on renal function&#xD;
      reducing the glomerular filtration rate, and have been shown to activate the RAA system.&#xD;
&#xD;
      Lixivaptan is a potent, non-peptide selective antagonist of the vasopressin V2 receptor.&#xD;
&#xD;
      Lixivaptan treatment results in increased free water excretion, thus decreasing urine&#xD;
      osmolality, increasing urine flow, and increasing serum osmolality. Short-term treatment with&#xD;
      lixivaptan has demonstrated improved fluid management and electrolyte balance in HF patients.&#xD;
&#xD;
      This study was designed to assess the effects of vasopressin blockade with lixivaptan in&#xD;
      patients with CHF with volume overload. A placebo-control arm will allow for assessment of&#xD;
      the effect of lixivaptan in addition to standard diuretic therapy as compared with standard&#xD;
      diuretic therapy alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy and safety of lixivaptan treatment in congestive heart failure (CHF) patients with volume expansion.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of lixivaptan treatment in CHF patients with volume expansion.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Lixivaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule, 100mg Lixivaptan or matching placebo once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixivaptan</intervention_name>
    <description>Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.</description>
    <arm_group_label>Lixivaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the purpose and risks of the study and to provide signed and&#xD;
             dated informed consent.&#xD;
&#xD;
          -  Men and women aged 18 years or older.&#xD;
&#xD;
          -  History of chronic CHF defined as requiring standard HF treatment (including&#xD;
             diuretics) for a minimum of 30 days.&#xD;
&#xD;
          -  Documented LVEF by any method within 12 months prior to screening.&#xD;
&#xD;
          -  The patient has clinical evidence of volume overload at the time of inclusion with at&#xD;
             least one of the following:&#xD;
&#xD;
               -  Dyspnea&#xD;
&#xD;
               -  Pulmonary congestion (rales)&#xD;
&#xD;
               -  Peripheral edema&#xD;
&#xD;
               -  Increased jugular venous pressure and/or hepatic congestion with ascites&#xD;
&#xD;
               -  Chest x-ray consistent with CHF&#xD;
&#xD;
               -  Plasma brain natriuretic peptide (BNP) ≥150 pg/mL or N-terminal prohormone brain&#xD;
                  natriuretic peptide (NT pro-BNP) ≥450 pg/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant (positive pregnancy test), breastfeeding, or who will not&#xD;
             adhere to the reproductive precautions as outlined in this protocol and in the&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          -  Sustained (three blood pressure measurements over 1 hour) systolic blood pressure &lt;90&#xD;
             mmHg at Screening or Day 0.&#xD;
&#xD;
          -  ST segment elevation myocardial infarction or stroke within 30 days prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Hemodynamically destabilizing cardiac arrhythmia within 30 days prior to Day 0.&#xD;
&#xD;
          -  Clinically significant valvular disease.&#xD;
&#xD;
          -  Known clinically significant obstructive, restrictive, or hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Cardiac surgery or percutaneous coronary intervention within 30 days prior to Day 0.&#xD;
&#xD;
          -  Major surgical procedure within 7 days prior to Day 0.&#xD;
&#xD;
          -  Likely to undergo cardiac transplantation, left ventricular assist device (LVAD) or&#xD;
             other device implantation, or other cardiac surgery within 3 months after Screening.&#xD;
&#xD;
          -  Placement of implantable cardioverter defibrillator or cardiac resynchronization&#xD;
             therapy device within 60 days prior to Day 0.&#xD;
&#xD;
          -  CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid&#xD;
             cardiomyopathy.&#xD;
&#xD;
          -  Presence of any clinically significant (as determined by the Investigator)&#xD;
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&#xD;
             neurologic, dermatologic, psychiatric, oncologic, and/or other major disease that&#xD;
             might interfere with safe and compliant participation in this study.&#xD;
&#xD;
          -  Screening laboratory findings as follows:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3 times the&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  Total bilirubin &gt;2.0 mg/dL&#xD;
&#xD;
               -  Serum creatinine &gt;3.0 mg/dL&#xD;
&#xD;
               -  Hemoglobin &lt;9.0 g/dL&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by the Investigator (e.g., glycosylated&#xD;
             hemoglobin [HbA1c] &gt;9%).&#xD;
&#xD;
          -  History of chronic drug/medication abuse within the past 6 months; or current alcohol&#xD;
             abuse.&#xD;
&#xD;
          -  Co-morbid condition with an expected survival of less than 3 months.&#xD;
&#xD;
          -  Known allergy to any vasopressin antagonist or any condition for which treatment with&#xD;
             a vasopressin antagonist may present undue risk to the patient.&#xD;
&#xD;
          -  Current or recent administration (within 7 days of Day 0) of prohibited medications as&#xD;
             listed in Section 8.6.4 .&#xD;
&#xD;
          -  Participation in any other investigational study of drugs or devices within 30 days&#xD;
             prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mobile Heart Specialists, PC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Clinical</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nea Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Interventional Cardiology</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merced Heart Associates</name>
      <address>
        <city>Merced</city>
        <state>California</state>
        <zip>95340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Heart Institute and Research Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida, Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edgewater Medical Research Inc</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation/Research/Cardiovascular Specialists Lower Keys</name>
      <address>
        <city>Key West</city>
        <state>Florida</state>
        <zip>33040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Heart Group Research Center</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Executive Health and Research Associates, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In-Quest Medical Research, LLC</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Valley Clinical Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Care Cardiology Research, Inc</name>
      <address>
        <city>Ayer</city>
        <state>Massachusetts</state>
        <zip>01432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Cardiology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Limited</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Heart Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Cardiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Norfolk, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <disposition_first_submitted>June 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 28, 2011</disposition_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cesare Orlandi, MD, SVP, Clinical Development</name_title>
    <organization>Cardiokine Bioharma, LLC</organization>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Volume Overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

